The Serum Prolidase Enzyme Activity as a Biomarker for Evaluation of the Subclinical Vascular Damage in Children with Epilepsy

Nurettin Karacan, Mustafa Çalik¹, Halil Kazanmaz, Özlem Ethemoglu², Ahmet Güzelciçek, Sedat Yaşın³, Hasan Kandemir³, Emre Çeçen⁴

Departments of Pediatrics, ¹Pediatric Neurology, ²Neurology and ³Pediatric Oncology, Harran University School of Medicine, Sanliurfa, ⁴Department of Child and Adolescent Psychiatry, Celal Bayar University School of Medicine, Manisa, Turkey

Abstract

Background: Epilepsy is a chronic medical condition requiring long term or even lifelong therapy. Various researches have shown that epilepsy patients have vascular risk factors such as abnormal lipids, insulin, elevated oxidative stress, chronic inflammation, and subclinical atherosclerosis.

Objectives: The purpose of the present study was to determine serum prolidase enzyme activity as a biomarker in children taking antiepileptic drug treatment through comparison with control cases.

Materials and Methods: The present study group consists of 61 children (20 females, 41 males) with epilepsy and a control group was formed of 32 healthy individuals (14 females, 18 males). Aspectrophotometric method was used to measure serum prolidase enzyme activity.

Results: The epilepsy group demonstrated statistically significantly higher prolidase enzyme activity values when compared with the control group ($P = 0.003$). It was measured that the serum TOS and OSI values were significantly elevated in patients with epilepsy compared to controls ($P < 0.001$). However, serum TAS values were significantly lower in the epilepsy group than in the control group ($P = 0.032$).

Conclusions: These results supported that epileptic patients taking the antiepileptic treatment had increased serum prolidase enzyme activity, suggesting that it may show an increased risk of subclinical vascular damage related to both chronic inflammation and fibrotic process associated with degenerated collagen turnover. Therefore, serum prolidase enzyme activity could be considered a useful biomarker for evaluation of the subclinical vascular damage in children with epilepsy on some antiepileptic drugs.

Keywords: Biomarkers, children, epilepsy, oxidative stress, serum prolidase enzyme activity, vascular damage

Introduction

Epilepsy is defined as a chronic condition characterized by recurrent unprovoked seizures. It is a common and serious neurological condition that occurs globally and can be a cause of disability in developing countries. In most studies, epilepsy prevalence has been reported to be approximately 10.2–57/1000 in developing countries and 6–8/1000 in developed countries including Turkey. The goal of antiepileptic treatment in childhood is to make the patient completely seizure-free without negatively affecting the brain functions. Therefore, treatment of the patient can be started with the drug known to be the most effective and appropriate to epileptic syndrome or the type of seizure determined from the history of a video recording. By taking age and gender into consideration while making this choice, drugs are selected which can be easily used and which have the fewest side effects. When these different antiepileptic drugs are used over a prolonged period for patients with epilepsy, there may be some adverse effects containing metabolic and endocrine disorders, behavioral or psychiatric illness, idiosyncratic reactions, negative cognitive influences, and medication interactions. Furthermore, various researches have shown that epilepsy patients have vascular risk factors such as abnormal lipids, insulin, elevated oxidative stress, and elevated total plasma homocysteine. Recent studies have also reported that long-term some antiepileptic treatment may increase the risk of vascular damage in patients with epilepsy. It has been suggested that through the mechanism of endothelial dysfunction resulting from vascular inflammation, antiepileptic treatment in cases of intractable epilepsy could be a role in the pathogenesis of vascular damage.

Prolidase enzyme activity is required for collagen biosynthesis and plays an important role in the breakdown of collagen and the intracellular proteins, especially in the final stage when imidodipeptides containing C-terminal proline or hydroxyproline are cleaved. Collagen is essential for the maintenance of connective tissue, and increased rates of collagen synthesis may lead to a change in the quality of collagen fibres.

Address for correspondence: Dr. Mustafa Calik, Department of Pediatric Neurology, Harran University School of Medicine, Osmanbey Campus, Sanliurfa, Turkey. E-mail: m.calik80@hotmail.com

Submitted: 05-Dec-2019 Revised: 23-Dec-2019 Accepted: 07-Feb-2020
Published: 29-Jun-2020

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

DOI: 10.4103/aiain.AIAN_640_19
This enzyme is known to be active in human plasma and different organs.\textsuperscript{[19,20]} The activity of prolidase enzyme is site-dependent with highest activities in the jejunum. Moreover, the studies indicated that fasting had different effects on the duodenal, jejunal, and colonic prolidase activities with the jejunal prolidase as the one most prone to dietary regulation.\textsuperscript{[21]}

Prolidase enzyme activity and the pathophysiological role of prolidase have investigated some diseases such as lung cancer, hypertension, acute hemorrhagic stroke, and epilepsy.\textsuperscript{[22-25]}

To our knowledge, there is no study regarding the serum prolidase enzyme activity in childhood epileptic patients. The goal of the present study is to evaluate the level of oxidative stress and serum prolidase enzyme activity in patients taking some antiepileptic treatment and control cases.

**Methods**

The present prospective investigation was supplied by February 2014 to April 2016 in the division of pediatric neurology of a tertiary university hospital, in Turkey. The acceptance of the present study was granted by the University Ethics Committee with respect to the Second Declaration of Helsinki (Date: 12.12.2014, No: 12). Written informed consent was obtained from the parents or legal guardians of these children. Evaluations were made of children aged 1–16 years with epilepsy, who were presented at the pediatric neurology outpatient clinic. The clinical, biochemical, electroencephalography, and brain magnetic resonance imaging (MRI) findings of epilepsy patients were evaluated and recorded in the follow-up.

The study group patients were those with at least 6 months of epilepsy with medical treatment. Blood samples were taken for examination in a period when the patient had no complaints, no acute infection table and were not using any drugs other than antiepileptic drugs. The control group comprised apparently healthy age and gender-matched children who were not using any medical drugs and had no chronic systemic or cardiovascular disease.

The serum samples were collected from these subjects within biochemical tubes. These samples were immediately centrifuged to separate plasma and accumulated at -20°C for analysis. Serum total antioxidant status (TAS) and total oxidant status (TOS) were measured using the automated evaluation method advanced by Erel.\textsuperscript{[26,27]} The oxidative stress index (OSI) was described as the percentage rate of TAS values to TOS values. It is formulated as: OSI (Arbitrary Unit) = TOS (mmol H$_2$O$_2$ Equivalent/L)/TAS (mmol Trolox Equivalent/L).

A spectrophotometric method measuring proline levels was used to evaluate serum prolidase enzyme activity.

All statistical analyses in the study were performed using SPSS\textsuperscript{®} for Windows version 18.0 software (Chicago, IL, USA). The Kolmogorov-Smirnov test was applied to quantitative data to determine conformity to normal distribution and values were stated as arithmetic means and standard deviations. The Chi-square test was applied to compare the demographic characteristics of groups. The comparison of continuous variables between two groups was performed with the student’s $t$-test. The results were accepted as statistically significant if a value of $P$ was <0.05.

**Results**

The patient’s group composed of 61 children (41 males, 20 females) with epilepsy and the control group comprised 32 healthy children (18 males, 14 females). The mean age of the epilepsy group was 8.07 ± 5.05 years, while that of the control group was 7.74 ± 5.63 years. There were no statistically significant differences about the age and gender between two groups ($P = 0.947$) [Table 1]. The epilepsy type was found to be focal epilepsy in 14 cases, generalized epilepsy in 39 cases, and unclassified epilepsy in 8 cases. Of the 61 epilepsy patients, 27 were taking monotherapy and 34 were taking polytherapy [Table 1].

In the patients using polytherapy, 15 cases (44, 12%) were taking two antiepileptic drugs, 13 cases (38, 23%) were taking three antiepileptic drugs, and six cases (17, 65%) were taking four antiepileptic drugs.

The brain MRI examinations demonstrated abnormality in 27 of 61 patients. These abnormalities include cortical dysplasia (3), porencephalic cyst (4), periventricular leukomalacia (8), multicystic encephalomalacia (3), hydrocephaly (2), mesial temporal sclerosis (1), and subependymal nodules (1) and nonspecific gliosis (5).

We measured that the serum TOS and OSI values were significantly elevated in patients with epilepsy compared to controls ($P < 0.001$). However, serum TAS values were

| Table 1: Demographic and clinical parameters of the epilepsy patient and control groups |
|-------------------------------------------------|-----------------|-----------------|
| Age, (years)                                      | 8.07±5.05       | 7.74±5.63       |
| Gender, Female/Male, (n)                           | 20/41           | 14/18           |
| BMI (kg/m$^2$)                                    | 16.9±4.42       | 17.4±4.25       |
| Number of AED, (n)                                | 1.9±1.02        | -               |
| Duration (years)                                  | 5.1±3.25        | -               |
| Epilepsy type, (n)                                |                |                 |
| Focal Epilepsy                                    | 14              | -               |
| Generalized Epilepsy                              | 39              | -               |
| Unclassified Epilepsy                             | 8               | -               |
| Brain MRI Finding, (n)                            |                |                 |
| Normal                                           | 34              | -               |
| Abnormal                                         | 27              | -               |
| AED Therapy, (n)                                  |                |                 |
| Monotherapy                                      | 27              | -               |
| Polytherapy                                       | 34              | -               |

*Student’s $t$-test, BMI: Body mass index, AED: Antiepileptic drug, MRI: Magnetic resonance imaging, values are mean±SD, significance was defined as $P<0.05$
significantly lower in the epilepsy group than in the control group ($P = 0.032$) [Table 2 and Figure 1].

The mean serum prolidase enzyme activity was 444.70±22.23 U/L in the epileptic patients and 366.44 ± 17.43 U/L in the controls. Thus, epilepsy group demonstrated statistically significantly higher prolidase activity values when compared with the control group ($P = 0.003$) [Table 2 and Figure 2].

**Discussion**

Oxidative stress has been defined as a disturbance of the equilibrium between the prooxidant and antioxidant systems in favor of prooxidation. The term oxidative stress is used to describe a number of chemical reactions involved in the production of free radicals and other reactive molecules that could potentially cause cellular injury.[28-30] Moreover, increased oxidative stress has been shown to play an important role in the pathogenesis of acute and chronic cerebral diseases.[30,31]

The findings obtained in this study demonstrated that there may be impaired oxidative status and increased serum prolidase enzyme activity in children using some antiepileptic medication.

Recent studies have shown increases in several oxidative stress indicators in epilepsy cases and this has strengthened the opinion that increased oxidative stress may contribute to some complications of epilepsy.[12-14] There are also various current studies that have speculated that long-term some antiepileptic drug use may alter serum lipids and may predispose the patient to vascular damage associated with chronic inflammation later in life. To investigate the development of vascular damage in epileptic children, several methods have been used containing different techniques.[17,32-39]

In a study of Egyptian patients with epilepsy, El-Farahaty et al. evaluated the atherosclerotic side effects of long-term antiepileptic treatment.[16] The serum fasting lipid profile was studied and biochemical, hormonal, and radiological imaging techniques were used in their study. The study concluded that following long-term monotherapy treatment using valproate, carbamazepine, lamotrigine, and topiramate. There were alterations in the biomarkers of vascular inflammation which could exacerbate atherosclerosis whereas the effect of levetiracetam was seen to be minimal. Similarly, in a study of 64 children with epilepsy by Sonmez et al. the effects of phenobarbital, carbamazepine, and valproate were evaluated on serum lipid profiles and lipoprotein (a).[37] It was concluded that treatment with phenobarbital, carbamazepine, and sodium valproate led to a considerable increase in serum lipoprotein values. In another cross-sectional study, intima-media thickness was determined to be significantly elevated in pediatric epileptic cases following monotherapy with either carbamazepine or phenytoin monotherapy for more than 18 months, compared to children in the controls.[35] However, Tokgoz et al. found no abnormalities in intima-media thickness evaluations in epilepsy patients compared to a control group.[38]

Similar to those results, it was observed that total oxidative values in the epileptic children were higher than those of the controls whereas the total antioxidative values were lower compared to the controls.[36,37,39] Increased oxidative stress index values were also determined in the current study patients with epilepsy [Figure 1]. These findings suggest that some antiepileptic treatment may be related to changes in the

**Table 2: Mean serum TAS, TOS, and OSI values and prolidase activities in the epilepsy patients and control group**

| Parameters                  | Patients $(n = 61)$ | Controls $(n = 32)$ | $P^*$  |
|-----------------------------|--------------------|--------------------|--------|
| TAS, ($\mu$mol Trolox equiv/L) | 1.13±0.33          | 2.09±1.04          | 0.032  |
| TOS, ($\mu$mol H$_2$O Equivalent/L) | 52.07±13.21       | 42.15±8.17         | <0.001 |
| OSI, (Arbitrary Unit)       | 4.89±2.03          | 2.53±1.17          | <0.001 |
| Prolidase Activity, (U/L)   | 444.70±22.23       | 366.44±17.43       | 0.003  |

* Student’s t-test, OSI: Oxidative stress index, TAS: Total antioxidant status, TOS: Total oxidant status

**Figure 1: Oxidative and antioxidative parameters in the patient and control groups**

**Figure 2: Comparison of serum prolidase activities in the patient and control groups**
circulatory biomarkers of vascular inflammation which may then contribute to the acceleration of preclinical atherosclerosis and increased vascular damage in epileptic patients.

Prolidase, an exopeptidase with a significant role in collagen metabolism, is the main regulating enzyme in the metabolism of proline and hydroxyproline containing about 20% of total human collagen.\[20\] In previous studies, elevated serum prolidase activity has been associated with various diseases including diabetic neuropathy, liver fibrosis, bipolar disorder, anxiety disorder, and many other brain disorders.\[40‑43\] Recently, Ozozen et al. have evaluated oxidative stress, inflammation, and the fibrotic process by measuring serum prolidase activity of adult with primary generalized epilepsy and they not found statistically significant differences in serum prolidase activity between patients with epilepsy and members of the healthy control group.\[25\]

In our study, we investigated serum prolidase activity (to evaluate collagen metabolism) and oxidative stress markers. This study showed that children with epilepsy have significantly increased serum prolidase activity and oxidative stress levels. Moreover, we found that there is an association between the oxidative–antioxidative status and prolidase activity in children with epilepsy.

The findings of the current study were not consistent with those of the study of Ozozen et al. with respect to serum prolidase activity in adult epileptic patients. The difference between the present study and other study is most likely related to the difference in the age ranges of the subjects. Epileptic children also may be more sensitive to external factors such as antiepileptic drug treatment than adults.

Toy et al. showed that compared with a control group, babies with intrauterine growth retardation had elevated serum prolidase enzyme activity.\[44\] In addition, Sezen et al. demonstrated significantly decreased serum prolidase enzyme activity in adult patients with cardiomyopathy while Yildiz et al. investigated the relationship both serum prolidase enzyme activity and the presence of coronary artery disease in adult patients.\[45,46\] In their study, serum prolidase enzyme activity was found to be higher in patients with coronary artery disease than in controls. In addition, a study by Demirbag et al. reported increased serum prolidase enzyme activity in hypertensive patients compared to a control group.\[23\]

In the current study, an important increase was seen in serum prolidase enzyme activity and oxidative stress index values in the epileptic children compared with the control group [Figure 2]. This finding is in accordance with the findings of similar studies that have investigated serum prolidase enzyme activity in patients with various disorders. The elevated serum prolidase enzyme activity and oxidative stress levels in the epileptic children in the current study suggest that both chronic inflammation and fibrotic process related to degenerated collagen turnover. Thus, these results may demonstrate the development of endothelial cell dysfunction and subclinical vascular damage.

The main limitation of this study was exclusively the use of biochemical methods. In addition, we did not measure the levels of tissue prolidase activity present study. However, we have published a new study showing similar results using radiological and cardiologic imaging methods in our clinic.\[47\]

**Conclusion**

In conclusion, the findings of this study supported that epileptic patients taking some antiepileptic drug treatment had elevated serum prolidase enzyme activity which could suggest an increased risk of subclinical vascular damage. Hence, it was hypothesized that elevated serum prolidase enzyme activity may be a useful biomarker for the evaluation of the subclinical vascular damage in epileptic children. Further clinical studies are needed on this subject.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Camfield PR, Camfield CS. Pediatric epilepsy: An overview. In: Swaiman KF, Ashwal S, Ferriero DM, Sehgal NF. editors. Swaiman’s Pediatric Neurology. 5th ed. New York: Elsevier; 2012. p. 951-8.
2. Weaver DF, Pohlmann-Eden B. Pharmacoresistant epilepsy: Unmet needs in solving the puzzle (s). Epilepsia 2013;54:80-5.
3. Maremmani C, Rossi G, Bonuccelli U, Murri L. Descriptive epidemiologic study of epilepsy syndromes in a district of Northwest Tuscany, Italy. Epilepsia 1991;32:294-8.
4. Rwiza HT, Kilonzo GP, Haule J, Matuja WB, Meza I, Mbena P, et al. Prevalence and incidence of epilepsy in Ulanga, a rural Tanzanian district: A community-based study. Epilepsia 1992;33:1051-6.
5. Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia 1994;35:1-6.
6. Serdaroglu A, Ozkan S, Aydin K, Gucleyener K, Tezcan S, Aycan S. Prevalence of epilepsy in Turkish children between the ages of 0 and 16 years. J Child Neurol 2004;19:271-4.
7. Mung’ala-Odera V, White S, Meehan R, Otieno GO, Njuguna P, Muri N, et al. Prevalence, incidence and risk factors of epilepsy in older children in rural Kenya. Seizure 2008;17:396-404.
8. Campolat M, Kumandas S, Poyrazoglu HG, Gumus H, Elmalı F, Per H. Prevalence and risk factors of epilepsy among school children in Kayseri City Center, an urban area in Central Anatolia, Turkey. Seizure 2014;23:708-16.
9. Nabbout R, Andrade DM, Bahi-Buisson N, Cross H, Desquerre I, Dulac O, et al. Outcome of childhood-onset epilepsy from adolescence to adulthood: Transition issues. Epilepsy Behav 2017;69:161-9.
10. Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia 2000;41:42-52.
11. Kim JY, Lee HW. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 2007;48:1366-70.
12. Verrotti A, Scardapane A, Franzoni E, Manco R, Chiarelli F. Increased oxidative stress in epileptic children treated with valproic acid. Epilepsy Res 2008;78:171-7.

13. Belcastro V, D’Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res 2013;107:1-8.

14. Kim DW, Lee SY, Shon YM, Kim JH. Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy. Epilepsia 2013;54:146-9.

15. Hamed SA. Atherosclerosis in epilepsy: Its causes and implications. Epilepsy Behav 2014;41:290-6.

16. Tan TY, Lu CH, Chuang HY, Lin TK, Liou CW, Chang WN, et al. Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia 2009;50:1579-86.

17. Calik M, Oguz E, Sarikaya S, Kocaturk O, Koca B, Gungor HE, et al. An evaluation of serum paraoxonase together with alyseresterase activities and oxidative stress in children with intractable epilepsy: A cross-sectional study. Epilepsy Res 2014;108:1591-96.

18. Keenan N, Sadlier LG, Wiltshire E. Vascular function and risk factors in children with epilepsy: Associations with sodium valproate and carbamazepine. Epilepsy Res 2014;108:1087-94.

19. Zanahoni G, Dyne KM, Rossi A, Monafò V, Cetta G. Prolidase deficiency: Biochemical study of erythrocyte and skin fibroblast prolidase activity in Italian patients. Haematologica 1994;79:13-8.

20. Kitchener RL, Grunden AM. Prolidase function in proline metabolism and its medical and biotechnological applications. J Appl Microbiol 2012;113:233-47.

21. Hu M, Cheng Z, Zheng L. Functional and molecular characterization of rat intestinal prolidase. Pediatr Res 2005;53:905-14.

22. Karne E, Surazynski A, Palka J. Collagen metabolism disturbances are accompanied by an increase in proline activity in lung carcinoma plano epithelioma. Int J Exp Pathol 2000;8:341-7.

23. Demirbag R, Yildiz A, Gur M, Yilmaz R, Gür M, Altiparmak IH, Akyol S, et al. Serum prolidase activity in children with hypertension and its relation with left ventricular hypertrophy. Clin Biochem 2007;40:1020-5.

24. Gonullu H, Aslan M, Karadas S, Kati C, Duran L, Milanolgolu A, et al. Serum proline and proline oxide activities and oxidative stress levels in patients with acute hemorrhagic stroke. Scand J Clin Lab Invest 2014;74:199-205.

25. Oozozen Ayas Z, Kotan D, Akdogan M, Gunel ME. Serum proline and proline oxide enzyme activity level: Not a predictive biomarker for epilepsy. EurAsian J Med 2019;51:27-30.

26. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112-9.

27. Erel O. A new automated colorimetric method for measuring total antioxidant status. Clin Biochem 2005;38:1103-11.

28. Winyard PG, Moody CJ, Jacob C. Oxidative activation of antioxidant defence. Trends Biochem Sci 2005;30:453-61.

29. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609-23.

30. Patel M, Li QY. Age dependence of seizure-induced oxidative stress. Neuroscience 2003;118:431-7.

31. Shin EJ, Jeong JH, Chung YH, Kim WK, Ko KH, Bach JH, et al. Role of oxidative stress in epileptic seizures. Neurochem Int 2011;59:122-37.

32. Tekgel H, Demir N, Gokben S. Serum lipid profile in children receiving anti-epileptic drug monotherapy: Is it atherogenic? J Pediatr Endocrinol Metab 2006;19:1151-5.

33. Aggarwal A, Singh V, Batra S, Faridi MM, Sharma S. Effect of carbamazepine therapy on serum lipids in children with partial epilepsy. Pediatr Neurol 2009;40:94-7.

34. Erdemir A, Cullu N, Yils M, Demircioğlu F, Kir M, Cakmakci H, et al. Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain Dev 2009;31:713-6.

35. Sankhyan N, Gulati S, Hari S, Kabra M, Ramakrishnan L, Kalva V. Noninvasive screening for preclinical atherosclerosis in children on phenytoin or carbamazepine monotherapy: A cross sectional study. Epilepsy Res 2013;107:121-6.

36. El-Farahaty RM, El-Mitwalli A, Azzam H, Wasel Y, Elrakhawy MM, Hasanean BM. Atherosclerotic effects of long-term old and new antiepileptic drugs monotherapy: A cross-sectional comparative study. J Child Neurol 2015;30:451-7.

37. Sonmez FM, Demir E, Orem A, Yildirimis S, Orhan F, Aslan A, et al. Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J Child Neurol 2006;21:70-4.

38. Tokgoz H, Aydin K, Oran B, Kiyici A. Plasma leptin, neuropetptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate. Childs Nerv Syst 2012;28:1049-53.

39. Ayicek A, Iscan A. The effects of carbamazepine, valproic acid and phenobarbital on the oxidative and antioxidative balance in epileptic children. Eur Neurol 2007;57:65-9.

40. Sekel S, Altindag A, Saracoğlu G, Celik H, Aksoy N. Prolidase activity and its diagnostic performance in bipolar disorder. J Affect Disord 2011;129:84-6.

41. Uzar E, Tayan Y, Evliyaoglu O, Tuzcu A, Beyaz C, Acar A, et al. Serum proline activity and oxidative status in patients with diabetic neuropathy. Neurol Sci 2012;33:875-80.

42. Stanfliet JC, Locketz M, Berman P, Pillay TS. Evaluation of the utility of serum proline as a marker for liver fibrosis. J Clin Lab Anal 2015;29:208-13.

43. Ercan AC, Bahceci B, Polat S, Cenker OC, Bahceci I, Koroglu A, et al. Oxidative status and proline activities in generalized anxiety disorder. Asian J Psychiatr 2017;25:118-22.

44. Toy H, Camuzeuglu H, Ariöz DT, Kurt S, Celik H, Aksoy N. Serum proline activity and oxidative stress markers in pregnancies with intrauterine growth restricted infants. J Obstet Gynaecol Res 2009;35:1047-53.

45. Sezen Y, Bas M, Altiparmak H, Yildiz A, Buyukhatipoglu H, Faruk Dag O, et al. Serum proline activity in idiopathic and ischemic cardiomyopathy patients. J Clin Lab Anal 2010;24:213-8.

46. Yildiz A, Demirbag R, Yilmaz R, Gur M, Altiparmak IH, Ak yol S, et al. The association of serum proline activity with the presence and severity of coronary artery disease. Coron Artery Dis 2008;19:319-25.

47. Calik M, Ozkan HY, Ethemoglu O, Koca B, Karanasimaz H, Karacan N, et al. The measurement of both carotid intima-media thickness and epicardial adipose tissue thickness in children with epilepsy receiving antiepileptic drug therapy. Epilepsy Behav 2018;85:110-4.